• RegMed XB 2020 Annual Meeting

    RegMed XB 2020 Annual Meeting

    The second RegMed XB’s Annual Meeting was held in the Dutch National Railway Museum in Utrecht on 4 and 5 March. They were certainly very intense and exciting days, marked by the interactive, multidisciplinar and societal approach that characterizes the RegMed XB project.
  • High potential of renal organoids and tubuloids in the treatment of kidney diseases

    High potential of renal organoids and tubuloids in the treatment of kidney diseases

    Researches from Hubrecht Institute and University Medical Center Utrecht, in collaboration with Radboud University Medical Center have recently published the paper “Kidney organoids and tubuloids” exploring the applications and challenges of these advanced in-vitro models..
  • Dutch-Flemish Memo of Understanding

    Dutch-Flemish Memo of Understanding

    Industrial Platform for Regenerative Medicineupscaling to affordable cure for chronic diseases As part of the political summit between the Netherlands and Flanders, a MoU (Memorandum of Understanding) on enhanced cooperation in the field of personalized medicine will be signed in...
  • 56 million euros from National Growth Fund

    56 million euros from National Growth Fund

    Maastricht, April 9, 2021 – Today the Dutch cabinet decided to fully fund the National Growth Fund application of RegMed XB. A maximum of 56 million euros will be available for setting up a pilot plant for regenerative medicine.... 
  • RegMed XB Global Launch

    RegMed XB Global Launch

    Growth towards a 'worldwide-consortium' accelerates healing for the chronically ill RegMed XB is working on new scaling up in Europe and the US RegMed XB (Regenerative Medicine Crossing Borders) is an international public-private...
  • 3rd NanoBio Surfaces and Interfaces in Healthcare and Science Workshop

    3rd NanoBio Surfaces and Interfaces in Healthcare and Science Workshop

    3rd NanoBio Surfaces and Interfaces in Healthcare and Science Workshop May 8-9, 2018 EPFL, Lausanne, Switzerland Chair: Prof. Philippe Renaud (EPFL) Keynote speakers: Roland Zengerle, Hahn-Schickard-Director Freiburg & Villingen-SchwenningenEmmanuel Delamarche, IBM Including - 2-day...
  • Binnen tien jaar nierfalen, diabetes en artrose genezen

    Binnen tien jaar nierfalen, diabetes en artrose genezen

    Volksziekten te lijf door René Steenhorst Nederlandse medische wetenschappers willen de komende tien jaar drie omvangrijke chronische ziekten genezen. Zij geloven patiënten met diabetes type 1, nierziekten en...
  • Biomedica On The Move

    Biomedica On The Move

    You are cordially invited for the 1st edition of Biomedica On The Move on Valorisation in Regenerative Medicine October 10, 2019 12.00 - 18.30 pm Brightlands Chemelot Campus Geleen, The Netherlands Register now free of cost for the first edition of the novel format of Biomedica,...
  • RegMed XB column in the Dutch patient magazine “Wisselwerking”

    RegMed XB column in the Dutch patient magazine “Wisselwerking”

    Within RegMed XB’s Kidney Moonshot work is done towards repairing kidneys or even growing new kidneys. The members of the Dutch patient association like to follow the progress of research that can be of vital importance to them. From October onward, the Dutch patient magazine “Wisselwerking” will feature a column about RegMed XB.
  • RegMed XB Researchers build mini-kidneys from urinary cells

    RegMed XB Researchers build mini-kidneys from urinary cells

    Scientists from Utrecht University, University Medical Center Utrecht and Hubrecht Institute have successfully created kidney organoids from urine cells. This could lead to a wide range of new treatments that...
  • One step closer to therapies based on cartilage regeneration

    One step closer to therapies based on cartilage regeneration

    Congratulations to Margot Rikkers on the publication of the paper “Importance of Timing of Platelet Lysate-Supplementation in Expanding or Redifferentiating Human Chondrocytes for Chondrogenesis” in the Preclinical Cell and Gene therapy section of Frontiers in Bioengineering and Biotechnology magazine.
  • The work goes on

    The work goes on

    Despite the rules imposed by the coronacrisis, our Moonshot projects are still going strong! This month we held a series of online Progress meetings with members of each of our four Moonshots to discuss the progress of the research in corona time. Luckily, progress is...
  • Great step forward in the Dutch regenerative medicine field

    Great step forward in the Dutch regenerative medicine field

    Leiden University Medical Center (LUMC), one of RegMed XB’s founding partners, has recently announced the construction of the largest non-profit stem cell and gene therapy facility in the Netherlands, and one of the largest...
  • Day one: First Townhall meeting RegMed XB successful!

    Day one: First Townhall meeting RegMed XB successful!

    Last Thursday 11 and Friday 12 March 2021, RegMed XB’s first online Townhall Event took place instead of the planned Annual Meeting. Read more about the first day here....
  • Launch of FIRST investment fund

    Launch of FIRST investment fund

    Launch of FIRST investment fund to accelerate development of solutions for prevention and cure of chronic diseases ensuring patients benefit earlier On February 13, during the Innovation for Health 2020 conference in Rotterdam, Focco Vijselaar, Director-General for Business and...
  • August Newsletter

    August Newsletter

    Dear all,As RegMed XB is going ahead full force, we are happy to provide you with regular updates on our accomplishments. Here you can download our very first newsletter in which you will find some information from our General Director (Prof....
  • Letter of Commitment Signed

    Letter of Commitment Signed

    RegMed XB accelerates the development of therapies for four chronic diseases Funding for the establishment of an industry for regenerative medicine On 15 November, a Letter of Commitment was signed in Utrecht by the partners of RegMed XB, an initiative in regenerative medicine....
  • More advances in research on kidney organoids

    More advances in research on kidney organoids

    Congratulations to Cathelijne W. van den Berg, on the publication of her paper “In Vivo Assessment of Size-Selective Glomerular Sieving in Transplanted Human Induced Pluripotent Stem Cell–Derived Kidney Organoids” in JASN magazine.
  • Day two: First Townhall meeting RegMed XB successful!

    Day two: First Townhall meeting RegMed XB successful!

    Last Thursday 11 and Friday 12 March 2021, RegMed XB’s first online Townhall Event took place instead of the planned Annual Meeting. Read more about the seccond day here....
  • RegMed XB Annual Meeting 2019 photos

    RegMed XB Annual Meeting 2019 photos

    RegMed XB Annual Meeting 2019 visual impression 6 and 7 February 2019 RegMed XB organised its first annual meeting with numerous lectures and workshops. On the second day there was a special sub-programme in which the public and patients were invited to gain knowledge about the...
  • Next building block for cartilage production

    Next building block for cartilage production

    Scinus Cell Expansion BV, a RegMed XB partner, has made the next step in bringing solutions to patients. Prometheus at KU Leuven, Belgium, installed a novel bioreactor from Scinus Cell Expansion B.V.
  • Update: International Conference of Tissue-Engineered Heart Valves

    Update: International Conference of Tissue-Engineered Heart Valves

    The first International Conference of Tissue Engineered Heart Valves (ICTEHV) is being held on May 18th 2018. Our expert speakers and the wide ranging program ensures that our conference is a must-attend event for...
  • Dokters van morgen

    Dokters van morgen

    Di 14 nov 21:25 • AVROTROS • 50 min RegMed XB wordt behandeld in de populaire documentaire-reeks Dokters van morgen.In de laatste aflevering van een documentaire-reeks over belangrijke innovaties in de zorg, is circa een half uur uitgetrokken voor het onderzoek...
  • First investment in potential medicine for stroke by FIRST-fund

    First investment in potential medicine for stroke by FIRST-fund

    The Utrecht-based company TargED Biopharmaceuticals received the first start-up funding from the FIRST fund, founded by the DCVA, RegMed XB and RVO. With the support of this new investment, the company can conduct follow-up research with their compound (Microlysis) that dissolves blood clots. The potential effect of this drug in strokes was discovered at UMC Utrecht.
  • RegMed XB in De Limburger (in Dutch)

    RegMed XB in De Limburger (in Dutch)

    Read the document published on delimburger.nl
  • Damage-Associated Molecular Patterns in Myocardial Infarction and Heart Transplantation: The Road to Translational Success

    Damage-Associated Molecular Patterns in Myocardial Infarction and Heart Transplantation: The Road to Translational Success

    Selma Kaffka genaamd Dengler, Clémence Odille, Mudit Mishra, Niels van der Kaaij, Pieter Doevensdans, Joost Sluijter and Saskia de Jager from the University Medical Center Utrecht published the paper “Damage-Associated Molecular Patterns in Myocardial Infarction and Heart Transplantation
  • New pro-bono collaboration with Trailblazers

    New pro-bono collaboration with Trailblazers

    Recently, a pro bono collaboration between RegMed XB’s Cardiovascular Moonshot and the software development company Trailblazers has started. Trailblazers has offered its expertise to help develop a software plugin. This plugin will enable automation of...
  • RegMed XB press release

    RegMed XB press release

    Robust new institute for regenerative medicine The Netherlands and Belgium are working on a world-class institute for innovation RegMed XB is the new institute for regenerative medicine. REGMED XB (REGenerative MEDicine Crossing Borders) will see health...
  • “Renal replacement therapy in Regenerative Medicine”

    “Renal replacement therapy in Regenerative Medicine”

    Thomas Geuens, Vanessa LaPointe and Clemens van Blitterswijk from MERLN Institute of Maastricht University have published the paper “Overcoming kidney organoid challenges for regenerative medicine” discussing the recent advances and remaining challenges for kidney organoids to become successful in regenerative medicine.
  • The Ethics of Synthetic Embryology: A Blessing or a Curse?

    The Ethics of Synthetic Embryology: A Blessing or a Curse?

    “Should human embryo-like structures be considered human embryos? If not, do they resemble human embryos so closely that they should still be due some moral and legal protection? If so, to what extent and in virtue of what exactly? Are there particular stages or events in embryogenesis from which synthetic embryologists should always steer away?”
  • Automation Entrepreneurs Receive Regional Subsidy

    Automation Entrepreneurs Receive Regional Subsidy

    Dutch Startup Nestegg Biotech B.V. has been awarded the "Limburg Makers Innovation Project" subsidy to fund development of Obruza laboratory automation system. This subsidy is expected to accelerate the development of a modular,...
  • RegMed XB start nieuwe moonshot voor hart- en vaatziekten

    RegMed XB start nieuwe moonshot voor hart- en vaatziekten

    RegMed XB organiseert op 6 en 7 februari haar jaarlijkse bijeenkomst met talloze lezingen en workshops. Speciale aandacht is er voor een nieuwe moonshot met het doel om stapsgewijs nieuwe therapieën te ontwikkelen voor hart-...
  • Vlaamse subsidiëring samenwerkingsprojecten regeneratieve geneeskunde

    Vlaamse subsidiëring samenwerkingsprojecten regeneratieve geneeskunde

    Subsidiëring samenwerkingsprojecten regeneratieve geneeskunde De Vlaams-Nederlandse topontmoeting in 2016 leidde tot afspraken over de versterking, verbreding en verdieping van de high...
  • RegMed XB welcomes new General Director, Bernard Mulder

    RegMed XB welcomes new General Director, Bernard Mulder

    The Supervisory Board of RegMed XB is excited to announce the appointment of Bernard Mulder as General Director, effective March 1, 2020. Bernard joins RegMed XB from Boehringer Ingelheim, where he led the Medical Affairs Department...
  • An ex vivo human osteochondral culture model

    An ex vivo human osteochondral culture model

    Congratulations to Meike W.A. Kleuskens on the publication of her paper “An ex vivo human osteochondral culture model” in the Journal of Orthopaedic Research.
  • First beating heart experiments outside the body

    First beating heart experiments outside the body

    The Dutch newspaper Algemeen Dagblad has published an article on the Cardiovascular Moonshot. For this article, an experiment at the laboratory of LifeTec Group was followed and two key researchers, as well as a patient, were...
  • €8 million impulse for regenerative and cardiovascular medicine

    €8 million impulse for regenerative and cardiovascular medicine

    Collaboration between researchers and venture capitalists accelerates innovation A collaboration between Regenerative Medicine Crossing Borders (RegMed XB) and the Dutch CardioVascular Alliance (DCVA) will receive an...

Have something to share?

Now you can contribute to keep our news section fresh and up-to date with relevant events and grants, research results and high impact publications related to REGMED XB’ Moonshots. Contributions can be sent to This email address is being protected from spambots. You need JavaScript enabled to view it.. Please submit the text in English and include a short title. We are looking forward to your input!

  • Diabetes FondsDiabetes Fonds
  • Leids Universitair Medisch CentrumLeids Universitair Medisch Centrum
  • Provincie UtrechtProvincie Utrecht
  • RijksoverheidRijksoverheid
  • Health HollandHealth Holland
  • Maastricht UMC+Maastricht UMC+
  • Provincie LimburgProvincie Limburg
  • TU/eTU/e
  • NierstichtingNierstichting
  • Provincie Noord-BrabantProvincie Noord-Brabant
  • Universiteit LeidenUniversiteit Leiden
  • LeidenLeiden
  • Stichting DONStichting DON
  • ReumaNederlandReumaNederland
  • Maastricht UniversityMaastricht University
  • UMC UtrechtUMC Utrecht
  • Utrecht UniversityUtrecht University
  • KU LeuvenKU Leuven
  • VIBVIB
  • HartstichtingHartstichting
  • 300Microns300Microns
  • Access2boneAccess2bone
  • Chemelot InSciTeChemelot InSciTe
  • Cyto smartCyto smart
  • Dutch CardioVascular AllianceDutch CardioVascular Alliance
  • Flanders State of the ArtFlanders State of the Art
  • FUJIFILMFUJIFILM
  • GalápagosGalápagos
  • HCM MedicalHCM Medical
  • Kuros BiosciencesKuros Biosciences
  • LifeTec GroupLifeTec Group
  • MateriomicsMateriomics
  • MimetasMimetas
  • Ministerie van Economische Zaken en KlimaatMinisterie van Economische Zaken en Klimaat
  • Ministerie van Onderwijs Cultuur en WetenschapMinisterie van Onderwijs Cultuur en Wetenschap
  • Ministerie van Volksgezondheid, Welzijn en SportMinisterie van Volksgezondheid, Welzijn en Sport
  • NcardiaNcardia
  • Nestegg BiotechNestegg Biotech
  • NTrans TechnologiesNTrans Technologies
  • Ostheo PharmaOstheo Pharma
  • Provincie Zuid-HollandProvincie Zuid-Holland
  • ScinusScinus
  • Starfish InnovationsStarfish Innovations
  • StentitStentit
  • SupraPolixSupraPolix
  • veldlaserveldlaser
  • VisualsonicsVisualsonics
  • XeltisXeltis

Information for

Contact information

  • Stichting REGMED XB
  • Minderbroedersberg 4-6, 6211 LK  Maastricht
  • This email address is being protected from spambots. You need JavaScript enabled to view it.

Connect with us

Copyright © 2020 RegMed XB. All rights reserved
Realisation & design by Joomlapartner